Viral Vectors Market by Application and Geography - Forecast and Analysis 2022-2026
| Published: Aug 2022 | Pages: 137 | SKU: IRTNTR40121 |
The viral vectors market share is expected to increase by USD 490.64 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 14.23%.
The viral vectors market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers viral vectors market segmentation by application (gene therapy and vaccines) and geography (North America, Europe, Asia, and Rest of World (ROW))
The viral vectors market report also offers information on several market vendors, including Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc among others.
Batavia Biosciences BV is a privately held company headquartered in The Netherlands. It is a global company, with limited information regarding its financials and limited information regarding its employee strength is available. Its revenue from the global viral vectors market is a key component of its overall revenues. The company offers a wide range of viral vectors such as adenoviruses and lentiviruses.
What will the Viral Vectors Market Size be During the Forecast Period?
Get the Viral Vectors Market Size Forecast by Downloading the Report Sample
Parent Market Analysis
Technavio categorizes the global viral vectors market as a part of the global healthcare equipment market. Our research report extensively covers external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the viral vectors market during the forecast period.
Viral Vectors Market: Key Drivers, Trends, and Challenges
Based on our research output, there has been a neutral impact on the market growth during and post-COVID-19 era. The rising prevalence of chronic diseases is notably driving the viral vectors market growth, although factors such as challenges associated with the production and manufacturing of viral vectors may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Viral Vectors Market Driver
The rising prevalence of chronic diseases is one of the key drivers supporting the viral vectors market growth. Despite advances in treatment options, the prevalence and incidence of several life-threatening diseases are rising. According to the CDC, in 2020, an estimated 1.1 million adults and adolescents were living with HIV in the US. In 2020, in the US, 30,635 individuals who were diagnosed with HIV died. According to the European Centre for Disease Prevention and Control (ECDC), in 2020, in Europe, 560 000 people in the EU and the European Economic Area (EEA) were diagnosed with HIV. Thus, the rising prevalence and incidence of such diseases have encouraged vendors to develop curative therapies using viral vectors. Hence, the rising prevalence and incidence of such diseases will drive the growth of the market during the forecast period.
Key Viral Vectors Market Trend
The increasing number of R&D activities for the development of gene therapies and vaccines using viral vectors is one of the key viral vectors market trends contributing to the market growth. Primarily, researchers are focusing on the development of gene therapies and vaccines using viral vectors, which will drive the growth of the market during the forecast period. For instance, Lokon Pharma AB is conducting a Phase I/II clinical trial to evaluate LOAd703, together with the standard of care chemotherapy, on patients with cancer, including pancreatic, biliary, colorectal, and ovarian cancer. OAd703 is an immunostimulatory gene therapy that uses a selection replication-competent adenovirus vector. Such an increasing number of R&D activities for the development of gene therapies and vaccines using viral vectors will fuel the growth of the market during the forecast period.
Key Viral Vectors Market Challenge
Challenges associated with the production and manufacturing of viral vectors is one of the factors hindering the viral vectors market growth. Viral vectors have emerged as the preferred vehicle in ongoing gene therapy trials. Recombinant adeno-associated virus-based vectors are the most widely used of all gene therapy products that are in development. They show high potential for delivery in gene therapy indications, such as cancer. However, the development of manufacturing processes for novel viral vectors is time-consuming and expensive. From the perspective of the development of wide gene therapies, current scale-up approaches are not adequate to supply the required number of doses to allow late-stage clinical trials to progress, which hinders the development of gene therapy products. Moreover, during process manipulation, steps can result in damage to viral capsids leading to loss of infectivity and functionality. Such challenges may hinder the production and manufacturing of viral vectors, which will affect the growth of the market during the forecast period.
This viral vectors market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Viral Vectors Market Value Chain Analysis
Our In-house experts produce extensive information on the value chain and parent market of the viral vectors market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-to-end understanding of product insight and profit and also optimization and evaluation of business strategies. The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.
Which are the Key Regions for Viral Vectors Market?
Get a glance at the market share of various regions by Requesting a PDF Sample now!
39% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the viral vectors market in North America. Market growth in this region will be slower than the market growth in Europe and Asia.
The strong prevalence of infectious and non-infectious diseases and the increasing investments in developing gene therapies and vaccines will facilitate the viral vector market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The regional market witnessed slow growth, especially in 2020 and 2021, owing to the outbreak of COVID-19. However, viral vector-based COVID-19 vaccines were produced, which positively impacted the market in 2021. Research institutes and healthcare facilities engaged in gene therapy started developing new gene therapy products and treatments for individuals with cancer, which increased the demand for viral vectors. Hence, the increasing focus of research institutes and gene therapy vendors on developing innovative gene therapies is expected to drive the growth of the market during the forecast period.
What is the Fastest-Growing Application Segment in the Viral Vectors Market?
Request a PDF Sample to gain insights into the market contribution of various segments
The viral vectors market share growth in the gene therapy segment will be significant during the forecast period. Viral vectors are used for the treatment of various disorders, such as hematologic, metabolic, cardiovascular, ophthalmologic, and infectious diseases, as well as diverse types of cancer. The use of viral vectors in gene therapy is a method that has the potential to achieve the direct, targeted, in vivo delivery of genes into the host. The characteristics of a viral vector for gene therapy include its easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects. Such characteristics of gene therapy will boost the market growth in the coming years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the viral vectors market size and actionable market insights on the post-COVID-19 impact on each segment.
|
Viral Vectors Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
137 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 14.23% |
|
Market growth 2022-2026 |
$ 490.64 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
12.28 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key consumer countries |
US, Canada, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Viral Vectors Market Report?
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will drive viral vectors market growth during the next five years
- Precise estimation of the viral vectors market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the viral vectors industry across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of viral vectors market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.3 Market size 2021
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Application
- 5.1 Market segments
- Exhibit 24: Chart on Application - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Application - Market share 2021-2026 (%)
- 5.2 Comparison by Application
- Exhibit 26: Chart on Comparison by Application
- Exhibit 27: Data Table on Comparison by Application
- 5.3 Gene therapy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Gene therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Gene therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Gene therapy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Gene therapy - Year-over-year growth 2021-2026 (%)
- 5.4 Vaccines - Market size and forecast 2021-2026
- Exhibit 32: Chart on Vaccines - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Vaccines - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Vaccines - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Vaccines - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Application
- Exhibit 36: Market opportunity by Application ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 UK - Market size and forecast 2021-2026
- Exhibit 62: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.9 China - Market size and forecast 2021-2026
- Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 Japan - Market size and forecast 2021-2026
- Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.1 Market drivers
- 8.2 Market challenges
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
- 8.4 Market trends
9 Vendor Landscape
- 9.1 Overview
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Batavia Biosciences BV
- Exhibit 85: Batavia Biosciences BV - Overview
- Exhibit 86: Batavia Biosciences BV - Product / Service
- Exhibit 87: Batavia Biosciences BV - Key offerings
- 10.4 Bayer AG
- Exhibit 88: Bayer AG - Overview
- Exhibit 89: Bayer AG - Business segments
- Exhibit 90: Bayer AG - Key offerings
- Exhibit 91: Bayer AG - Segment focus
- 10.5 Creative Biogene
- Exhibit 92: Creative Biogene - Overview
- Exhibit 93: Creative Biogene - Product / Service
- Exhibit 94: Creative Biogene - Key offerings
- 10.6 F. Hoffmann La Roche Ltd.
- Exhibit 95: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 96: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 97: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 98: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 99: F. Hoffmann La Roche Ltd. - Segment focus
- 10.7 FinVector Oy
- Exhibit 100: FinVector Oy - Overview
- Exhibit 101: FinVector Oy - Product / Service
- Exhibit 102: FinVector Oy - Key offerings
- 10.8 FUJIFILM Holdings Corp
- Exhibit 103: FUJIFILM Holdings Corp - Overview
- Exhibit 104: FUJIFILM Holdings Corp - Business segments
- Exhibit 105: FUJIFILM Holdings Corp - Key offerings
- Exhibit 106: FUJIFILM Holdings Corp - Segment focus
- 10.9 Lonza Group Ltd.
- Exhibit 107: Lonza Group Ltd. - Overview
- Exhibit 108: Lonza Group Ltd. - Business segments
- Exhibit 109: Lonza Group Ltd. - Key news
- Exhibit 110: Lonza Group Ltd. - Key offerings
- Exhibit 111: Lonza Group Ltd. - Segment focus
- 10.10 Merck KGaA
- Exhibit 112: Merck KGaA - Overview
- Exhibit 113: Merck KGaA - Business segments
- Exhibit 114: Merck KGaA - Key news
- Exhibit 115: Merck KGaA - Key offerings
- Exhibit 116: Merck KGaA - Segment focus
- 10.11 Oxford Biomedica Plc
- Exhibit 117: Oxford Biomedica Plc - Overview
- Exhibit 118: Oxford Biomedica Plc - Business segments
- Exhibit 119: Oxford Biomedica Plc - Key offerings
- Exhibit 120: Oxford Biomedica Plc - Segment focus
- 10.12 Thermo Fisher Scientific Inc.
- Exhibit 121: Thermo Fisher Scientific Inc. - Overview
- Exhibit 122: Thermo Fisher Scientific Inc. - Business segments
- Exhibit 123: Thermo Fisher Scientific Inc. - Key news
- Exhibit 124: Thermo Fisher Scientific Inc. - Key offerings
- Exhibit 125: Thermo Fisher Scientific Inc. - Segment focus
11 Appendix
- 11.1 Scope of the report
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
viral vectors market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis